-
1 × ₨ 462.40
-
1 × ₨ 120.00
-
1 × ₨ 320.00
-
1 × ₨ 392.83
-
1 × ₨ 10.00
-
1 × ₨ 43.00
-
1 × ₨ 109.00
-
1 × ₨ 384.00
-
1 × ₨ 360.00
-
1 × ₨ 28.50
-
1 × ₨ 432.00
-
1 × ₨ 392.00
-
1 × ₨ 320.00
-
1 × ₨ 490.00
-
1 × ₨ 55.80
-
1 × ₨ 325.00
-
1 × ₨ 455.00
-
1 × ₨ 820.77
-
1 × ₨ 134.00
-
1 × ₨ 256.00
-
1 × ₨ 880.00
-
1 × ₨ 720.00
-
1 × ₨ 166.00
-
1 × ₨ 621.00
-
1 × ₨ 471.93
-
1 × ₨ 236.00
Roll over image to zoom in
SITAPIN 50MG
₨ 277.00₨ 308.00 (-10%)
- For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
- Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
Sitagliptin is a new oral hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. The drug works to competitively inhibit a protein/enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an increased amount of active incretins (GLP-1 and GIP), reduced amount of release of glucagon (diminishes its release) and increased release of insulin.
Reviews
There are no reviews yet.